Results 301 to 310 of about 5,785,146 (400)

The role and application of bioinformatics techniques and tools in drug discovery. [PDF]

Front Pharmacol
Zhang S, Liu K, Liu Y, Hu X, Gu X.
europepmc   +1 more source

Targeting of myosin light chain kinase in vascular smooth muscle cells, and its implication for drug discovery.

, 2001
Kazuhiro Kohama, Akio Nakamura
openalex   +2 more sources

Serotonergic and Dopaminergic Function in Neuropsychiatrically Asymptomatic People With HIV on Antiretroviral Therapy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective People with HIV (PWH) on antiretroviral therapy (ART) still experience neurocognitive dysfunction and accelerated brain volume loss. To assess whether the serotonergic and dopaminergic systems are affected, we used [11C]DASB positron emission tomography (PET) to assess presynaptic serotonergic function and [18F]FDOPA PET to measure ...
Chuen‐Yen Lau, Anna Lyndaker, Swati Shah, Paul Wakim, Amelia Mitchell, Cynthia Monroe, Alan Kim, Tracy L. Cropper, Govind Nair, Joseph Snow, Bryan R. Smith, Avindra Nath, Dima A. Hammoud   +12 more
wiley   +1 more source

DrugGen enhances drug discovery with large language models and reinforcement learning. [PDF]

Sci Rep
Sheikholeslami M, Mazrouei N, Gheisari Y, Fasihi A, Irajpour M, Motahharynia A.   +5 more
europepmc   +1 more source

From Genomic Drug Discovery to Tailor-made Medicine

, 2001
Toshio Furuya
openalex   +2 more sources

CSF Biomarker‐Based Cognitive Trajectories in Parkinson's Disease‐Subjective Cognitive Decline

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cognitive complaints without objective cognitive impairment in Parkinson's Disease, termed Parkinson's Disease‐Subjective Cognitive Decline (PD‐SCD), have been associated with cognitive decline. However, its progression is heterogeneous, highlighting the need for improved identification of patients at greater risk for deterioration ...
Jon Rodriguez‐Antiguedad, Arnau Puig‐Davi, Iñigo Ruíz‐Barrio, Javier Pagonabarraga, Anna Vázquez‐Oliver, Andrea Horta‐Barba, Jaime Kulisevsky, Saül Martínez‐Horta   +7 more
wiley   +1 more source

The Nature of Nanodisc Lipids Influences Fragment-Based Drug Discovery Results. [PDF]

Chem Biol Drug Des
Knetsch TGJ, van Son H, Kobayashi M, Ubbink M.   +3 more
europepmc   +1 more source

Advantage of cassette dosing in ADME screening at drug discovery stage

, 2001
Yuka Iwamoto, Ryo Norikura, Noboru Okamura, Hiroshi Okabe, Takahiko Baba, Masahiro Koike, Takayoshi Yoshikawa   +6 more
openalex   +2 more sources

An Analysis for IDH‐Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Purpose There is ongoing debate regarding the therapeutic approach and prognosis for IDH‐mutant grade 4 astrocytoma, a newly defined subtype of diffuse glioma in the 2021 WHO classification system for central nervous system tumors (WHO CNS 5). The aim of this study was to explore the clinical outcome and prognosticators for newly diagnosed IDH‐
Xianxin Qiu, Liping Liang, Lingchao Chen, Pengjie Hong, Wanzun Lin, Jiabing Liu, Zhirui Zhou, Wenjia Zhu, Tianqi Wu, Mingyuan Pan, Yihua Zhong, Jing Gao, Zhiyong Qin, Yang Wang   +13 more
wiley   +1 more source

Traditional Chinese medicine for sepsis: advancing from evidence to innovative drug discovery. [PDF]

Crit Care
Ji Y, Song H, Li L.
europepmc   +1 more source